Published in Clin Neuropharmacol on April 30, 2002
Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc (2009) 2.34
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep (2007) 2.31
Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe. J Med Internet Res (2011) 2.19
Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proc Natl Acad Sci U S A (2007) 1.43
Treatment of narcolepsy and other hypersomnias of central origin. Sleep (2007) 1.42
Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry (2005) 1.42
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol (2008) 1.34
Modafinil and memory: effects of modafinil on Morris water maze learning and Pavlovian fear conditioning. Behav Neurosci (2009) 1.21
2-(Methyl-sulfin-yl)benzamide. Acta Crystallogr Sect E Struct Rep Online (2010) 1.16
Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One (2013) 0.94
The ethics of elective psychopharmacology. Int J Neuropsychopharmacol (2011) 0.85
Daytime sleepiness in elderly Parkinson's disease patients and treatment with the psychostimulant modafinil: A preliminary study. Neuropsychiatr Dis Treat (2010) 0.84
Agitation and psychosis associated with dementia with lewy bodies exacerbated by modafinil use. Am J Alzheimers Dis Other Demen (2012) 0.82
Behavioral effects of modafinil in marmoset monkeys. Psychopharmacology (Berl) (2006) 0.82
Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.79
Sleepiness and Unintended Sleep in Parkinson's Disease. Curr Treat Options Neurol (2003) 0.78
Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis (2015) 0.78
Differential effects of wake promoting drug modafinil in aversive learning paradigms. Front Behav Neurosci (2015) 0.76
Excessive daytime sleepiness and unintended sleep episodes associated with Parkinson's disease. Oman Med J (2015) 0.76
Modafinil: Parkinson disease-related somnolence. Hosp Pharm (2014) 0.75
Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. Front Neurol (2016) 0.75
Evaluating and Managing Sleep Disorders in the Parkinson's Disease Clinic. Basal Ganglia (2016) 0.75
Modafinil in sports: ethical considerations. Br J Sports Med (2005) 0.75
Effects of Modafinil on Behavioral Learning and Hippocampal Synaptic Transmission in Rats. Int Neurourol J (2015) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54
Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord (2009) 1.53
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51
Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. Brain (2004) 1.47
Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord (2004) 1.46
Long-term hardware-related complications of deep brain stimulation. Neurosurgery (2002) 1.46
Motor cortical stimulation for parkinsonism in multiple system atrophy. Arch Neurol (2003) 1.45
Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord (2008) 1.45
Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45
The fragile X premutation presenting as essential tremor. Arch Neurol (2003) 1.43
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol (2006) 1.42
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol (2002) 1.40
Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39
Definition and classification of hyperkinetic movements in childhood. Mov Disord (2010) 1.38
Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol (2006) 1.34
Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol (2012) 1.32
Gait abnormalities in psychogenic movement disorders. Mov Disord (2007) 1.32
Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol (2006) 1.31
Apraxia in movement disorders. Brain (2005) 1.29
The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet (2004) 1.29
Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol (2004) 1.28
The nonmotor symptoms of Parkinson's disease--an overview. Mov Disord (2010) 1.25
Movement disorders on YouTube--caveat spectator. N Engl J Med (2011) 1.25
The many faces of corticobasal degeneration. Parkinsonism Relat Disord (2007) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord (2003) 1.19
Crossroads in GDNF therapy for Parkinson's disease. Mov Disord (2006) 1.19
Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol (2010) 1.16
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol (2004) 1.14
Pallidal neuronal activity: implications for models of dystonia. Ann Neurol (2003) 1.14
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology (2013) 1.14
Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H2O PET study. Hum Brain Mapp (2009) 1.13
Dystonia in complex regional pain syndrome type I. Ann Neurol (2010) 1.13
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord (2006) 1.13
Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology (2003) 1.12
ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord (2009) 1.12